These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39031747)

  • 21. Exploring the therapeutic potential of Thai medicinal plants: in vitro screening and in silico docking of phytoconstituents for novel anti-SARS-CoV-2 agents.
    Maikhunthod B; Chaipayang S; Jittmittraphap A; Thippornchai N; Boonchuen P; Tittabutr P; Eumkeb G; Sabuakham S; Rungrotmongkol T; Mahalapbutr P; Leaungwutiwong P; Teaumroong N; Tanthanuch W
    BMC Complement Med Ther; 2024 Jul; 24(1):274. PubMed ID: 39030504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro biological evaluation and in silico insights into the antiviral activity of standardized olive leaves extract against SARS-CoV-2.
    Majrashi TA; El Hassab MA; Mahmoud SH; Mostafa A; Wahsh EA; Elkaeed EB; Hassan FE; Eldehna WM; Abdelgawad SM
    PLoS One; 2024; 19(4):e0301086. PubMed ID: 38662719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
    Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
    J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico screening of Allium cepa phytochemicals for their binding abilities to SARS and SARS-CoV-2 3C-like protease and COVID-19 human receptor ACE-2.
    Bondhon TA; Fatima A; Jannat K; Hasan A; Jahan R; Nissapatorn V; Wiart C; Pereira ML; Rahmatullah M
    Trop Biomed; 2021 Jun; 38(2):214-221. PubMed ID: 34172713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deciphering inhibitory activity of marine algae Ecklonia cava phlorotannins against SARS CoV-2 main protease: A coupled in-silico docking and molecular dynamics simulation study.
    Chakraborty A; Ghosh R; Barik S; Mohapatra SS; Biswas A; Chowdhuri S
    Gene; 2024 Oct; 926():148620. PubMed ID: 38821329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
    Abosheasha MA; El-Gowily AH; Elfiky AA
    J Thromb Thrombolysis; 2022 Feb; 53(2):273-281. PubMed ID: 34510337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marine Brominated Tyrosine Alkaloids as Promising Inhibitors of SARS-CoV-2.
    El-Demerdash A; Hassan A; Abd El-Aziz TM; Stockand JD; Arafa RK
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease.
    Deshmukh N; Talkal R; Lakshmi B
    J Biomol Struct Dyn; 2024 Jun; 42(9):4395-4411. PubMed ID: 37325819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potential phytochemicals from
    Khan J; Sakib SA; Mahmud S; Khan Z; Islam MN; Sakib MA; Emran TB; Simal-Gandara J
    J Biomol Struct Dyn; 2022; 40(21):10741-10752. PubMed ID: 34278965
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation.
    Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA
    J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors.
    Padhi S; Masi M; Chourasia R; Rajashekar Y; Rai AK; Evidente A
    Eur J Pharmacol; 2021 Jan; 890():173648. PubMed ID: 33069672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
    Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
    J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches.
    Raj V; Park JG; Cho KH; Choi P; Kim T; Ham J; Lee J
    Int J Biol Macromol; 2021 Jan; 168():474-485. PubMed ID: 33290767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insight into crystal structures and identification of potential styrylthieno[2,3-
    El Bakri Y; Ahmad B; Saravanan K; Ahmad I; Bakhite EA; Younis O; Al-Waleedy SAH; Ibrahim OF; Nafady A; Mague JT; Mohamed SK
    J Biomol Struct Dyn; 2024 May; 42(8):4325-4343. PubMed ID: 37318002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by
    Bhowmick S; Mistri TK; Khan MR; Patil PC; Busquets R; Ashif Ikbal AM; Choudhury A; Roy DK; Palit P; Saha A
    J Biomol Struct Dyn; 2024 Sep; 42(14):7107-7127. PubMed ID: 37482789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).
    El-Demerdash A; Metwaly AM; Hassan A; Abd El-Aziz TM; Elkaeed EB; Eissa IH; Arafa RK; Stockand JD
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33808721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.